The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Commentary|Videos|December 11, 2024
Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer
Author(s)Azka Ali, MD
Fact checked by: Ashling Wahner , Chris Ryan
Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.
Advertisement
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute, discusses updated findings from the phase 3 S0221 trial (NCT00070564) investigating alternative adjuvant anthracycline and taxane dosing schedules in patients with high-risk, early breast cancer.
Advertisement
Related to this article
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
The OncFive: Top Oncology Articles for the Week of 7/12
5